AU2007263265A1 - Differential IL-4 and/or IL-10 cytokine expression in human cancer - Google Patents

Differential IL-4 and/or IL-10 cytokine expression in human cancer Download PDF

Info

Publication number
AU2007263265A1
AU2007263265A1 AU2007263265A AU2007263265A AU2007263265A1 AU 2007263265 A1 AU2007263265 A1 AU 2007263265A1 AU 2007263265 A AU2007263265 A AU 2007263265A AU 2007263265 A AU2007263265 A AU 2007263265A AU 2007263265 A1 AU2007263265 A1 AU 2007263265A1
Authority
AU
Australia
Prior art keywords
tumour
cytokine
apoptotic
cells
chemotherapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007263265A
Other languages
English (en)
Inventor
Christian Gieffers
Oliver Hill
Giorgio Stassi
Meinolf Thiemann
Matilde Todaro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apogenix AG
Original Assignee
Apogenix AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apogenix AG filed Critical Apogenix AG
Publication of AU2007263265A1 publication Critical patent/AU2007263265A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2007263265A 2006-06-21 2007-06-21 Differential IL-4 and/or IL-10 cytokine expression in human cancer Abandoned AU2007263265A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06012754.5 2006-06-21
EP06012754 2006-06-21
PCT/EP2007/005480 WO2007147600A2 (en) 2006-06-21 2007-06-21 Differential il-4 and/or il-10 cytokine expression in human cancer

Publications (1)

Publication Number Publication Date
AU2007263265A1 true AU2007263265A1 (en) 2007-12-27

Family

ID=38359749

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007263265A Abandoned AU2007263265A1 (en) 2006-06-21 2007-06-21 Differential IL-4 and/or IL-10 cytokine expression in human cancer

Country Status (12)

Country Link
US (1) US20090324616A1 (enExample)
EP (1) EP2041576B1 (enExample)
JP (1) JP2010514409A (enExample)
CN (1) CN101529253A (enExample)
AT (1) ATE520032T1 (enExample)
AU (1) AU2007263265A1 (enExample)
BR (1) BRPI0713484A2 (enExample)
CA (1) CA2656379A1 (enExample)
DK (1) DK2041576T3 (enExample)
ES (1) ES2371287T3 (enExample)
RU (1) RU2009101783A (enExample)
WO (1) WO2007147600A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007107349A1 (en) * 2006-03-22 2007-09-27 Apogenix Gmbh Antibody specific for human il-4 for the treament of cancer
WO2008003514A2 (en) * 2006-07-06 2008-01-10 Apogenix Gmbh Human il-4 muteins in combination with chemotherapeutics or pro-apoptotic agents in cancer therapy
RU2648157C2 (ru) * 2012-07-18 2018-03-22 Аподжиникс Аг КОМПОЗИЦИЯ, ВКЛЮЧАЮЩАЯ СМЕСЬ ИЗОФОРМ CD95-Fc
WO2015138638A1 (en) 2014-03-11 2015-09-17 Theraly Pharmaceuticals, Inc. Long acting trail receptor agonists for treatment of autoimmune diseases
CA3003133C (en) * 2014-10-24 2020-09-15 StemImmune, Incorporated Combination immunotherapy approach for treatment of cancer
EA201800148A1 (ru) 2015-08-11 2019-01-31 Калиди Биотерапьютикс, Инк. Оспенная вакцина для лечения рака
ES3013312T3 (en) 2015-12-17 2025-04-11 Univ Johns Hopkins Ameliorating systemic sclerosis with death receptor agonists
US11084879B2 (en) 2016-04-07 2021-08-10 The Johns Hopkins University Compositions and methods for treating pancreatitis and pain with death receptor agonists
US20190317098A1 (en) * 2016-11-24 2019-10-17 Huvet Bio, Inc. Composition for diagnosis of diseases
US20210023132A1 (en) * 2017-09-06 2021-01-28 Fred Hutchinson Cancer Research Center Strep-tag specific chimeric receptors and uses thereof
US11505782B2 (en) 2018-06-04 2022-11-22 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
DE4137333A1 (de) * 1991-11-13 1993-05-19 W Prof Dr Sebald Therapeutische mittel, die antagonisten oder partielle agonisten des humanen interleukin 4 sind oder diese enthalten, hil-4-mutantenproteine sowie vefahren zu deren herstellung
US6534051B1 (en) * 1992-11-20 2003-03-18 University Of Medicine And Dentistry Of New Jersey Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins
BR9407575A (pt) 1993-09-07 1996-07-16 Smithkline Beecham Corp Recombinaçao il4 de anticorpos uteis no tratamento de desordens do il4
DE4423131A1 (de) * 1994-07-01 1996-01-04 Bayer Ag Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
CN1216992C (zh) * 1994-07-05 2005-08-31 史廷诺研究集团有限公司 免疫调节剂
CZ25697A3 (en) 1994-07-29 1997-09-17 Smithkline Beecham Plc Novel compounds
US6664227B1 (en) * 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
US5710023A (en) * 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
US20030124125A1 (en) * 1996-04-05 2003-07-03 South Alabama Medical Science Foundation Oncofetal antigen specific T-lymphocyte mediated immune response: manipulation and uses of oncofetal antigen specific CD4, CD8 cytotoxic and suppressor T cells and interleukin-10
US6028176A (en) * 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins
WO1999024069A1 (fr) * 1997-11-10 1999-05-20 Mochida Pharmaceutical Co., Ltd. Medicaments preventifs et therapeutiques pour des affections pulmonaires diffuses
JPH11312463A (ja) * 1998-04-28 1999-11-09 Hitachi Ltd 配線基板およびそれを用いたガス放電型表示装置
CA2404365A1 (en) * 2000-03-31 2001-10-11 Idec Pharmaceutical Corporation Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma
US20020076409A1 (en) * 2000-07-12 2002-06-20 March Carl J. Method for treating cancer
US20040023338A1 (en) * 2001-10-26 2004-02-05 Heavner George A. IL-4 mutein proteins, antibodies, compositions, methods and uses
EP1578912A4 (en) * 2001-10-26 2007-12-26 Centocor Inc IL-13 MUTEIN PROTEINS, ANTIBODIES, COMPOSITIONS, METHODS AND USES
EP1444989A1 (en) * 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
AU2005307831A1 (en) * 2004-11-17 2006-05-26 Amgen, Inc. Fully human monoclonal antibodies to IL-13
US20070122855A1 (en) * 2005-11-28 2007-05-31 Targetgen Inc. Methods for diagnosing hepatocellular carcinoma
WO2007107349A1 (en) * 2006-03-22 2007-09-27 Apogenix Gmbh Antibody specific for human il-4 for the treament of cancer
WO2008003514A2 (en) * 2006-07-06 2008-01-10 Apogenix Gmbh Human il-4 muteins in combination with chemotherapeutics or pro-apoptotic agents in cancer therapy

Also Published As

Publication number Publication date
RU2009101783A (ru) 2010-07-27
JP2010514409A (ja) 2010-05-06
DK2041576T3 (da) 2011-12-05
EP2041576A2 (en) 2009-04-01
ES2371287T3 (es) 2011-12-29
CA2656379A1 (en) 2007-12-27
WO2007147600A3 (en) 2008-04-10
ATE520032T1 (de) 2011-08-15
BRPI0713484A2 (pt) 2012-11-06
CN101529253A (zh) 2009-09-09
US20090324616A1 (en) 2009-12-31
EP2041576B1 (en) 2011-08-10
WO2007147600A2 (en) 2007-12-27

Similar Documents

Publication Publication Date Title
EP2041576B1 (en) Differential cytokine expression in human cancer
JP6812364B2 (ja) 癌診断用抗ｇｉｔｒ抗体
DK2533047T3 (en) CCR4 as a therapeutic target for cancer
CN108463246B (zh) 使用人生长分化因子15(gdf-15)抑制剂和免疫检查点阻断剂的联合治疗
CN105349618B (zh) 三阴性乳腺癌标记物及其在诊断和治疗中的应用
Schinagl et al. Oxidized macrophage migration inhibitory factor is a potential new tissue marker and drug target in cancer
JP2014505239A (ja) 癌の治療または検出のための抗ｃｘｃｌ１３および抗ｃｘｃｒ５抗体の使用
Costes et al. Expression of the interleukin 6 receptor in primary renal cell carcinoma.
Xie et al. Formyl peptide receptor 2 expression predicts poor prognosis and promotes invasion and metastasis in epithelial ovarian cancer
CA3076997C (en) Anti-ckap4 monoclonal antibody
Ekshyyan et al. Rapamycin targets Interleukin 6 (IL-6) expression and suppresses endothelial cell invasion stimulated by tumor cells
KR20210107730A (ko) 골수 형성이상 증후군의 치료 또는 예방에서의 il-1 베타 항체의 용도
Liu et al. Desensitization of T lymphocyte function by CXCR3 ligands in human hepatocellular carcinoma
Urra et al. Differential expression profile of CXCR3 splicing variants is associated with thyroid neoplasia. Potential role in papillary thyroid carcinoma oncogenesis?
WO2010066858A1 (en) Methods for the treatment and the prognosis of cancer
Castellani et al. Interaction of transforming growth factor‐alpha and epidermal growth factor receptor in breast carcinoma. An immunohistologic study
DK2585089T3 (en) CCL18 blockade of signaling through CCR6 as a therapeutic option in fibrotic diseases and cancer
US8969020B2 (en) Peptide sequence that promotes tumor invasion
US20120015352A1 (en) Method of determining sensitivity of human or non-human animal cells to an iap antagonist
Wu Circulating tumor markers of the new millennium: target therapy, early detection, and prognosis
JP2006507243A (ja) 癌に関係するタンパク質
Zhu et al. Expression of chemokines CCL5 and CCL11 by smooth muscle tumor cells of the uterus and its possible role in the recruitment of mast cells
Seol et al. Aggressive vestibular schwannomas showing postoperative rapid growth–their association with decreased p27 expression
EP4499875B1 (en) Biomarkers of il7r modulator activity
KR102268041B1 (ko) 구강암의 예후 예측용 조성물

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period